Association of Fibrinogen Variants with Severity of Obesity and Metabolic Liver Disease: 2-Year Follow-up after Bariatric Surgery

Abstract

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of obesity. Studies in mice link fibrinogen variation to obesity and MASLD, but how naturally occurring fibrinogen variants associate with obesity and MASLD in humans is unknown.

Objectives

To investigate associations of fibrinogen variants (fibrinogen γ', fibrinogen α_E, and sialylated fibrinogen) with obesity, MASLD, and fibrosis severity and examine changes in variants 2 years after bariatric surgery.

Methods

We included 195 individuals with a body mass index (BMI) > 35 kg/m². A subgroup of 93 individuals, who underwent bariatric surgery (n = 35) or served as nonsurgical control group (n = 58), were followed for 2 years. Hepatic tissue samples were scored for MASLD and fibrosis. Fibrinogen variants were measured using enzyme-linked immunosorbent assay.

Results

Absolute levels of fibrinogen variants tended to be higher in individuals with BMI > 45 kg/m² compared with BMI < 40 kg/m² (Δγ': 70 [95% confidence interval: −19, 160] µg/mL; Δα_E: 0.85 [−0.36, 2.06] µg/mL; Δsialylated: 0.09 [−0.05, 0.24] arbitrary units [AU]). Absolute and relative fibrinogen α_E levels increased with MASLD (Δα_E: 2.04 [0.74, 3.35] µg/mL; Δα_E ratio: 0.05 [0.02, 0.08] %) and fibrosis (Δα_E: 1.79 [0.48, 3.11] µg/mL; Δα_E ratio: 0.05 [0.02, 0.07] %), whereas relative fibrinogen γ' levels decreased with fibrosis (Δγ' ratio: −2.52 [−4.70, −0.35] %). After bariatric surgery, sialylated fibrinogen levels were lower (Δsialylated: −0.22 [−0.32, −0.11] AU), but relative levels of the fibrinogen variants were higher (Δγ': 1.7 [0.03, 3.30] %; Δα_E: 0.03 [0.001, 0.06] %; Δsialylated: 0.02 [0.002, 0.04] AU/g/L) compared with the control group.

Conclusion

Obesity, MASLD, and fibrosis alter fibrinogen variant profiles in plasma suggesting that fibrinogen variation plays a role in these inflammatory conditions.

Keywords

steatotic liver - fibrin - fibrosis - inflammation

• References

• 1 Lee ECZ, Anand VV, Razavi AC. et al. The global epidemic of metabolic fatty liver disease. Curr Cardiol Rep 2024; 26 (04) 199-210
• 2 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64 (01) 73-84
• 3 Lisman T, Jenne CN. Fibrin fuels fatty liver disease. J Thromb Haemost 2018; 16 (01) 3-5
• 4 Kopec AK, Abrahams SR, Thornton S. et al. Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest 2017; 127 (08) 3152-3166
• 5 Asghar A, Sheikh N. Role of immune cells in obesity induced low grade inflammation and insulin resistance. Cell Immunol 2017; 315: 18-26
• 6 Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci 2017; 18 (08) 18
• 7 Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood 2019; 133 (06) 511-520
• 8 Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. 3. Identification of chain variants. J Biol Chem 1972; 247 (16) 5223-5227
• 9 Chung DW, Davie EW. Gamma and gamma' chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23 (18) 4232-4236
• 10 Fu Y, Grieninger G. Fib420: a normal human variant of fibrinogen with two extended alpha chains. Proc Natl Acad Sci U S A 1994; 91 (07) 2625-2628
• 11 Grieninger G, Lu X, Cao Y. et al. Fib420, the novel fibrinogen subclass: newborn levels are higher than adult. Blood 1997; 90 (07) 2609-2614
• 12 Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003; 102 (02) 535-540
• 13 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2567-2573
• 14 Mosesson MW, DiOrio JP, Hernandez I, Hainfeld JF, Wall JS, Grieninger G. The ultrastructure of fibrinogen-420 and the fibrin-420 clot. Biophys Chem 2004; 112 (2-3): 209-214
• 15 Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J 2016; 33 (03) 309-343
• 16 Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem 2017; 82: 405-456
• 17 de Vries JJ, Snoek CJM, Rijken DC, de Maat MPM. Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and fibrinolysis: a systematic review. Arterioscler Thromb Vasc Biol 2020; 40 (03) 554-569
• 18 Indira Chandran V, Wernberg CW, Lauridsen MM. et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology 2023; 77 (02) 558-572
• 19 Bedossa P, Poitou C, Veyrie N. et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56 (05) 1751-1759
• 20 Kleiner DE, Brunt EM, Van Natta M. et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (06) 1313-1321
• 21 Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol 1957; 17 (04) 237-246
• 22 Pedersen NB, Bladbjerg EM, Juhl CB. et al. Validation of a fibrinogen γ' enzyme-linked immunosorbent assay using a new monoclonal antibody: effects of bariatric surgery. Res Pract Thromb Haemost 2024; 8 (01) 102319
• 23 Daugaard N, Bladbjerg EM, Lundsgaard Svane HM. et al. Association of fibrinogen α_E, fibrinogen γ', and sialylated fibrinogen with development of ischemic stroke in patients with recently diagnosed type 2 diabetes. J Thromb Haemost 2025;S1538-7836(25)00203-X
• 24 Stolberg CR, Mundbjerg LH, Funch-Jensen P, Gram B, Juhl CB, Bladbjerg EM. Effects of gastric bypass followed by a randomized study of physical training on markers of coagulation activation, fibrin clot properties, and fibrinolysis. Surg Obes Relat Dis 2018; 14 (07) 918-926
• 25 Lovely R, Hossain J, Ramsey JP. et al. Obesity-related increased γ' fibrinogen concentration in children and its reduction by a physical activity-based lifestyle intervention: a randomized controlled study. J Pediatr 2013; 163 (02) 333-338
• 26 Lishko VK, Yakubenko VP, Hertzberg KM, Grieninger G, Ugarova TP. The alternatively spliced alpha(E)C domain of human fibrinogen-420 is a novel ligand for leukocyte integrins alpha(M)beta(2) and alpha(X)beta(2). Blood 2001; 98 (08) 2448-2455
• 27 Besser MW, MacDonald SG. Acquired hypofibrinogenemia: current perspectives. J Blood Med 2016; 7: 217-225
• 28 Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983; 61 (06) 1196-1202
• 29 Pezzino S, Luca T, Castorina M, Puleo S, Latteri S, Castorina S. Role of perturbated hemostasis in MASLD and its correlation with adipokines. Life (Basel) 2024; 14 (01) 93
• 30 Martinez J, Keane PM, Gilman PB, Palascak JE. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Ann N Y Acad Sci 1983; 408: 388-396